CST, 67686S, DAF/CD55 Antibody

Polyclonal Antibody for studying CD55. Validated for Western Blotting. Highly specific and rigorously validated in-house, DAF/CD55 Antibody (CST #67686) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity DAF/CD55 Antibody recognizes endogenous levels of total CD55/DAF protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human DAF/CD55 protein. Antibodies are purified by protein A and peptide affinity chromatography. Background Decay-accelerating factor (DAF/CD55) is a GPI-linked plasma membrane glycoprotein normally expressed on the surface of vascular endothelial and hematopoietic cells, which are continuously exposed to autologous complement components. In conjunction with other membrane complement regulatory proteins (CD35, CD46, and CD59), DAF/CD55 protects healthy cells from inappropriate complement-mediated lysis (1). DAF/CD55 inhibits activation of the complement cascade by promoting membrane dissociation and inactivation of C3 convertase, which inhibits amplification of the classical and alternative complement cascades (2). Research studies have demonstrated that DAF/CD55 is overexpressed in a variety of solid and liquid tumors, which functions to protect tumor cells from complement-mediated attack (3,4). Given its ability to disable the complement cascade and facilitate immune evasion by tumor cells, DAF/CD55 has received attention as a potential therapeutic target for the treatment of human malignancies. CD55 deficiency is also linked to human disease. The inability to express CD55 on the surface of erythrocytes renders them highly susceptible to complement-mediated lysis, which contributes to the development of paroxymal noctural hemoglobinuria (PNH). PNH is characterized by hemolytic anaemia, pancytopenia, and venous thrombosis (5). Alternate Names CD55; CD55 antigen; CD55 molecule (Cromer blood group); CD55 molecule, decay accelerating factor for complement (Cromer blood group); CHAPLE; Complement decay-accelerating factor; CR; CROM; Cromer blood group antigen; DAF; decay accelerating factor for complement; Rh blood group D antigen; TC Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 78 SOURCE: Rabbit